Search

Your search keyword '"Aiba, S."' showing total 669 results

Search Constraints

Start Over You searched for: Author "Aiba, S." Remove constraint Author: "Aiba, S." Database MEDLINE Remove constraint Database: MEDLINE
669 results on '"Aiba, S."'

Search Results

2. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.

3. Successful treatment of pustulotic arthro-osteitis with amoxicillin: A case report and review of the literature.

4. Low proviral load in the Kumamoto strain of Japanese Brown cattle infected with the bovine leukemia virus.

5. An international validation study of the interleukin-2 luciferase leukocyte toxicity test (IL-2 Luc LTT) to evaluate potential immunosuppressive chemicals and its performance after use with the interleukin-2 luciferase assay (IL-2 Luc assay).

6. Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis.

7. The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors.

8. Cohort study of subclinical sensitization against galactose-α-1,3-galactose in Japan: Prevalence and regional variations.

9. Staphylococcus aureus skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis.

10. Evaluation of Anterior Coverage in Children With Developmental Dysplasia of the Hip Using Transverse Magnetic Resonance Imaging at 2 Years Is Predictive of Future Radiographic Coverage.

11. Loss of IκBζ Drives Dentin Formation via Altered H3K4me3 Status.

12. Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells.

13. Characterization of rosacea patients in Tohoku area of Japan: Retrospective study of 340 rosacea cases.

14. Functional Analysis of the Transcriptional Regulator IκB-ζ in Intestinal Homeostasis.

15. Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report.

17. Ehlers-Danlos syndrome type IV with a novel COL3A1 exon 14 skipping variation confirmed by Tohoku Medical Megabank Organization genomic database.

18. Body mass index, HbA1c and serum C-reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital-based retrospective case-control study.

19. GWAS Identified IL4R and the Major Histocompatibility Complex Region as the Associated Loci of Total Serum IgE Levels in 9,260 Japanese Individuals.

20. Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients.

22. 2020 guidelines for the diagnosis and treatment of cutaneous pruritus.

23. 2020 guidelines for the diagnosis and treatment of prurigo.

24. Pediatric psoriasis induced by HLA-B46-Cw1 haplotype: A retrospective study of psoriasis onset after hematopoietic stem cell transplantation.

25. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.

26. Optimization of the IL-2 Luc assay for immunosuppressive drugs: a novel in vitro immunotoxicity test with high sensitivity and predictivity.

27. [A Case of Upper Urinary Tract Stone in an Infant].

29. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.

31. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients.

32. Improvement of diagnostic markers for resistance to Globodera pallida and application for selection of resistant germplasms in potato breeding.

34. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma.

35. The IL-1 promoter-driven luciferase reporter cell line THP-G1b can efficiently predict skin-sensitising chemicals.

36. Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid.

37. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.

38. Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma.

39. Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.

40. The modified IL-8 Luc assay, an in vitro skin sensitisation test, can significantly improve the false-negative judgment of lipophilic sensitizers with logK ow values > 3.5.

41. Facial UV photo imaging for skin pigmentation assessment using conditional generative adversarial networks.

42. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.

44. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin.

45. Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.

46. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.

48. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy.

49. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma.

Catalog

Books, media, physical & digital resources